The number of patients living with end-stage heart failure is steadily growing. Although originally intended to serve solely as a bridge to more definitive surgical therapies, there is an increasing number of patients receiving inotropic therapy (milrinone, dobutamine) for purely palliative purposes. Continuous infusion may increase quality of life and reduce symptom burden at the cost of increasing mortality.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the American Medical Directors Association
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2022 Published by Elsevier Inc.